
Bcr-Abl
Les inhibiteurs de Bcr-Abl sont des thérapies ciblées qui inhibent la protéine de fusion Bcr-Abl, formée à la suite de la translocation du chromosome Philadelphie et moteur de la leucémie myéloïde chronique (LMC). Cette protéine influence également l'angiogenèse, contribuant à la progression tumorale. Les inhibiteurs de Bcr-Abl sont cruciaux dans le traitement de la LMC et sont explorés pour leur potentiel à inhiber l'angiogenèse dans divers cancers. Chez CymitQuimica, nous offrons des inhibiteurs de Bcr-Abl de haute qualité pour soutenir vos recherches en biologie du cancer, angiogenèse et thérapies ciblées.
102 produits trouvés pour "Bcr-Abl"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
SNIPER(ABL)-020
<p>SNIPER(ABL)-020, a Dasatinib-Bestatin conjugate via linker, inhibits ABL and targets IAP, reducing BCR-ABL protein.</p>Formule :C44H59ClN10O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :923.52SNIPER(ABL)-019
<p>SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting a</p>Formule :C60H77ClN12O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1177.85cSRC/BCR-ABL1-IN-1
<p>cSRC/BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC/BCR-ABL1 kinases.</p>Formule :C24H27ClN6O4Couleur et forme :SolidMasse moléculaire :498.96cSRC/BCR-ABL-IN-1
<p>cSRC/BCR-ABL-IN-1 (compound 21b) is a potent inhibitor of Bcr-Abl and C-Src, with IC50 values of 56.2 nM and 101 nM, respectively. It exhibits cytotoxicity.</p>Formule :C29H31Cl2N5O4Couleur et forme :SolidMasse moléculaire :584.494FGFRs-IN-1
<p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>Formule :C28H26Cl2N4O3Couleur et forme :SolidMasse moléculaire :537.44SNIPER(ABL)-013
<p>SNIPER(ABL)-013, a compound that links GNF5 (ABL inhibitor) with Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of</p>Formule :C42H52F3N7O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :839.9Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Couleur et forme :Odour SolidSNIPER(ABL)-050
<p>SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.</p>Formule :C68H84N12O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1213.47BCR-ABL-IN-9
<p>BCR-ABL-IN-9 (Compound B1) is an inhibitor of BCR-ABL that achieves sustained suppression through the formation of stable covalent bonds with the ABL kinase. It effectively inhibits the activity of ABL kinase (IC50 = 1.2 nM) and possesses anticancer activity.</p>Formule :C22H20N4O3Couleur et forme :SolidMasse moléculaire :388.42SIAIS178
CAS :<p>SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).</p>Formule :C50H62ClN11O6S2Degré de pureté :98.07%Couleur et forme :SolidMasse moléculaire :1012.68SNIPER(ABL)-033
CAS :<p>SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein</p>Formule :C61H73F3N10O9S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1211.42Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Couleur et forme :Odour SolidSNIPER(ABL)-044
<p>SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving a</p>Formule :C51H64F3N9O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1020.17AD57
CAS :<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Formule :C22H20F3N7ODegré de pureté :99.05%Couleur et forme :SoildMasse moléculaire :455.44Tyrosine kinase-IN-8
<p>Tyrosine kinase-IN-8 (compound 4e) is a BCR‐ABL1 tyrosine kinase inhibitor (TKI) exhibiting antiproliferative activity against the chronic myeloid leukemia (CML) cell line K562, with a CC50 of 0.8 µM. Tyrosine kinase-IN-8 is applicable for research in chronic leukemia.</p>Formule :C31H21F2N7O2Masse moléculaire :561.17248SNIPER(ABL)-049
<p>SNIPER(ABL)-049, a compound that conjugates Imatinib (ABL inhibitor) with Bestatin (IAP ligand) through a linker, effectively reduces BCR-ABL protein levels,</p>Formule :C52H66N10O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :959.14PROTAC BCR-ABL1 ligand 1
CAS :<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Formule :C17H12F3N3O2Couleur et forme :SoildMasse moléculaire :347.29SNIPER(ABL)-024
CAS :<p>SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,</p>Formule :C52H61F3N8O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1031.15SIAIS100
<p>SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.</p>Formule :C44H50ClF2N9O5SCouleur et forme :SolidMasse moléculaire :890.44BCR-ABL-IN-10
<p>BCR-ABL-IN-10 (compound B4) is a covalent BCR-ABL inhibitor featuring an arylvinylsulfonate (AVS) moiety, demonstrating an IC50 of 43.1 nM against ABL kinase. It forms a covalent and stable adduct with ABL kinase, enabling the sustained inhibition of intrinsic BCR-ABL activity. This compound is utilized in the study of chronic myeloid leukemia (CML).</p>Formule :C24H22N4O5SCouleur et forme :SolidMasse moléculaire :478.52

